| Identification | More | [Name]
4,4'-Methylenebis(3-hydroxy-2-naphthoic acid) disodium salt | [CAS]
6640-22-8 | [Synonyms]
1,1'-METHYLENE-BIS[2-HYDROXY-3-NAPHTHOIC ACID] DISODIUM SALT
2,2'-DIHYDROXY-1,1'-DINAPHTHYLMETHANE-3,3'-DICARBOXYLIC ACID DISODIUM SALT
4,4'-METHYLENEBIS(3-HYDROXY-2-NAPHTHOIC ACID) DISODIUM SALT
4,4'-METHYLENEBIS(3-HYDROXY-2-NAPHTHOIC ACID SODIUM SALT)
EMBONIC ACID DISODIUM SALT
PAMOIC ACID DISODIUM SALT
PAMOIC ACID NA
sodium pamoate
disodium 4,4'-methylenebis[3-hydroxy-2-naphthoate]
PAMOIC ACID DISODIUM
PAMOIC ACID DISODIUM SALT 98%
PAMOIC ACID DISODIUM SALT 98+%
DisodiumPamoate98%
DISODIUMEMBONATE
4,4μ-Methylenebis(3-hydroxy-2-naphthoic acid), Embonic acid, Sodium pamoate
2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, disodium salt
Disodium 4-[(3-carboxylato-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylate
1,1'-Methylenebis(2-hydroxy-3-naphthalenecarboxylic acid sodium) salt
1,1'-Methylenebis(2-hydroxy-3-naphthalenecarboxylic acid)disodium salt | [EINECS(EC#)]
229-653-1 | [Molecular Formula]
C23H14Na2O6 | [MDL Number]
MFCD00036183 | [Molecular Weight]
432.33 | [MOL File]
6640-22-8.mol |
| Chemical Properties | Back Directory | [Appearance]
pale yellow to yellow powder | [Melting point ]
300 °C
| [density ]
1.55[at 20℃] | [vapor pressure ]
0.001Pa at 25℃ | [storage temp. ]
Desiccate at RT | [solubility ]
insoluble in EtOH; ≥18 mg/mL in H2O; ≥28.6 mg/mL in DMSO | [form ]
solid | [color ]
Pale yellow | [Water Solubility ]
43g/L at 20℃ | [InChI]
1S/C23H16O6.Na.H/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;;/h1-10,24-25H,11H2,(H,26,27)(H,28,29);; | [InChIKey]
ZRZSXMUASGHHKP-UHFFFAOYSA-N | [SMILES]
[Na].OC(=O)c1cc2ccccc2c(Cc3c(O)c(cc4ccccc34)C(O)=O)c1O | [LogP]
-3.2 at 20℃ | [CAS DataBase Reference]
6640-22-8(CAS DataBase Reference) | [EPA Substance Registry System]
6640-22-8(EPA Substance) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed .
R37/38:Irritating to respiratory system and skin .
R41:Risk of serious damage to eyes.
R48:Danger of serious damage to health by prolonged exposure. | [Safety Statements ]
S24/25:Avoid contact with skin and eyes .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) .
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S22:Do not breathe dust . | [WGK Germany ]
3 | [TSCA ]
TSCA listed | [HS Code ]
2918.29.7500 | [REACH Registrations]
Active | [Storage Class]
11 - Combustible Solids |
| Hazard Information | Back Directory | [Chemical Properties]
pale yellow to yellow powder | [Uses]
Pamoic acid disodium salt, a supposedly inactive component in many formulations of drugs used to modulate release, is a potent agonist of the orphan receptor GPR35. GPR35 is a class A, rhodopsin-like G protein-coupled receptor (GPCR), strongly expressed in the lower intestine and colon, dorsal root ganglia, as well as a variety of immune cells including monocytes and dendritic cells. Targeting GPR35 provides potential therapeutic opportunities in a range of conditions, such as inflammation, pain and cancer. | [Flammability and Explosibility]
Notclassified | [Biological Activity]
Pamoic acid disodium salt is a GPR35 agonist. Induces GPR35 internalization and activates ERK1/2 (EC50 values are 22 and 65 nM respectively). Mediates recruitment of β-arrestin2 to GPR35. Also exhibits antinociceptive effects in a mouse model of visceral pain. | [in vivo]
Pamoic acid disodium (0-100 mg/kg; s.c.; once) induces a dose-related antinociception in the abdominal constriction test[1]. | Animal Model: | Swiss-Webster mice (30–35 g)[1] | | Dosage: | 25, 50, and 100 mg/kg | | Administration: | Subcutaneous injection, once | | Result: | Elicited dose-related antinociception, the dose causing 50% antinociception being 40.5 mg/kg. |
| [storage]
Desiccate at RT |
|
|